

USAMMDA INFORMATION PAPER

PRODUCT: FIBRINOGEN BANDAGE FOR BATTLEFIELD WOUNDS (CONGRESSIONAL)

DESCRIPTION: The Fibrinogen Bandage is intended to provide a revolutionary improvement in the control of severe life-threatening hemorrhage. The goal is to have a dressing that, when applied with direct pressure, will stop severe arterial and/or venous bleeding. Utilizing combinations of biologically compatible components that can be put on, or into a casualty, it is intended for use by the combat medic/combat lifesaver and other medical personnel on the battlefield.

PROGRAM RELEVANCE TO THE ARMY: This product supports both the core mission of the Army and the Army Campaign Plan. Of the Army's core competencies, this product supports "Forcible Entry Operations," "Sustained Land Dominance," and "Support of Civil Authorities." In any conflict or civilian disaster, it is an unfortunate fact that there will be casualties with severe bleeding. This product is intended to save soldiers' lives in those situations. The aid man and the combat lifesaver will use it far forward to reduce bleeding and allow the casualty to be evacuated to available medical assets further back, again reducing the logistical burden far forward. This product supports Future Operational Capabilities: MD-02-001 Clearing the Battlefield and MD-02-002 Hospitalization.

ISSUES/ACTIONS:

- This is a new product.
- The fibrinogen bandage will utilize transgenically produced clotting proteins.

ADDITIONAL INFORMATION:

BPL # 442

SCHEDULE:

DA PROJECT/TASK: Trauma Management –
PE/PROJ 643807/836AJ

TBD

MAMP RANK: 1/36

ARMY ORD: Approved, 28 April 1999

SOCOM ORD: Approved, 15 June 1998

For additional information, contact: Applied Medical Systems, DSN 343-7582, Comm. 301-619-7582